HPV vaccine and adolescents' sexual activity

HPV vaccine acceptance in male adolescents.

Publisher rights Copyright © 2015 John Wiley & Sons, Ltd. This is the peer reviewed version of the following article: Prue, G., and Santin, O. (2015) HPV vaccine acceptance in male adolescents. Psycho-Oncology, doi: 10.1002/pon.3961, which has been published in final form at http://onlinelibrary.wiley.com/doi/10.1002/pon.3961/abstract. This article may be used for non-commercial purposes in acc...

Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males.

A small number of HPV types are related to a majority of HPV-related neoplastic lesions in humans. High-risk types such as HPV 16 and 18 are most often implicated, although other oncogenic and non-oncogenic HPV types can cause disease in men. The efficacy of the quadrivalent HPV vaccine (qHPV) against external genital lesions and intra-anal disease related to HPV in men has been demonstrated. T...

HPV vaccine and adolescent males.

In 2009, the United States approved quadrivalent HPV vaccine for males 9-26 years old, but data on vaccine uptake are lacking. We determined HPV vaccine uptake among adolescent males, as well as stage of adoption and vaccine acceptability to parents and their sons. A national sample of parents of adolescent males ages 11-17 years (n=547) and their sons (n=421) completed online surveys during Au...

Patient information about HPV and the HPV vaccine.

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.

BACKGROUND The rate of anal cancer is increasing among both women and men, particularly men who have sex with men. Caused by infection with human papillomavirus (HPV), primarily HPV type 16 or 18, anal cancer is preceded by high-grade anal intraepithelial neoplasia (grade 2 or 3). We studied the safety and efficacy of quadrivalent HPV vaccine (qHPV) against anal intraepithelial neoplasia associ...